App-Quantinova.ai

Investigation of Lipid Metabolism Dysregulation in Chronic Lymphocytic Leukemia and the Role of ENPP2 in Tumorigenesis of Chronic Lymphocytic Leukemia

Liyan Lu - American Society of Hematology (ASH) , 2022

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Chronic Lymphocytic Leukemia

N/A

Orelabrutinib, Fludarabine, Cyclophosphamide, and Obinutuzumab (OFCG) for First-Line Treatment of Chronic Lymphocytic Leukemia: A Multicenter, Investigator-Initiated Study (cwCLL-001 study)

Huayuan Zhu - American Society of Hematology (ASH) , 2022

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Chronic Lymphocytic Leukemia

Cyclophosphamide

Anwulignan Suppresses Myeloma Growth By Pyroptosis

Wenzhuo Zhuang - American Society of Hematology (ASH) , 2022

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Multiple Myeloma

MD 1003

EGFR and HDAC Dual-Target Inhibitor CUDC-101 Enhances the Anti-Myeloma Effects of Bortezomib By Regulating the G2/M Cell Cycle Arrest

Wen Cao - American Society of Hematology (ASH) , 2022

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Multiple Myeloma

Bortezomib

Leonurine Promotes the Maturation of Healthy Donors and Multiple Myeloma Patients Derived-Dendritic Cells

Cheng Chen - American Society of Hematology (ASH) , 2022

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Multiple Myeloma

streptomycin

High Mutational Burden of Chromatin-Modifying Genes Defines a Relatively Indolent Subgroup of Plasma Cell Dyscrasias

Xuezhu Wang - American Society of Hematology (ASH) , 2022

Therapeutic Area

Disease

Drug/Treatment

Peripheral Nervous System

AL Amyloidosis

Cyclophosphamide

Magnetically Empowered Malignant Tumor Cells As Micro-Living Motors to Construct a Bone Original or Bone Metastasis Human-Mouse Chimera Tumor Model

Jialu Zhang - American Society of Hematology (ASH) , 2022

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Multiple Myeloma

N/A

ISG20L2 Suppresses Bortezomib Anti-Myeloma Activity By Attenuating Bortezomib Binding to PSMB5

Yan Yang - American Society of Hematology (ASH) , 2022

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Multiple Myeloma

carfilzomib Intravenous

FGFR1OP2 Promotes Proliferation and Survival of Myeloma Cells and Is a Potential Therapeutic Target

Yang Yang - American Society of Hematology (ASH) , 2022

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Multiple Myeloma

N/A

CD320 Regulates Bone Marrow Angiogenesis in Multiple Myeloma Via HGF-ERK Axis

Lingling Shu - American Society of Hematology (ASH) , 2022

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Multiple Myeloma

N/A

Identifying the Cells of Origin and Risk-Stratification Strategy By Single-Cell Sequencing in Multiple Myeloma

Lixin Gong - American Society of Hematology (ASH) , 2022

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Multiple Myeloma

N/A

Exosome Mirnas Profiling in Serum and Prognostic Evaluation in Patients with Multiple Myeloma

Teng Fang - American Society of Hematology (ASH) , 2022

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Multiple Myeloma

N/A

Chinese Herbal Medicine 'Diwu' Suppresses Myeloma Bone Disease Via ERK/MAPK Signaling Pathway By Targeting CCL3

Huiwen He - American Society of Hematology (ASH) , 2022

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Multiple Myeloma

N/A

Cytomegalovirus and Epstein-Barr Virus Infection during Daratumumab Treatment in Patients with Multiple Myeloma

Shuchan Li - American Society of Hematology (ASH) , 2022

Therapeutic Area

Disease

Drug/Treatment

Infectious Diseases (ID)

Multiple Myeloma

daratumumab Intravenous

A Multicenter Prospective Study for Validation of the Korean Simple Geriatric Assessment Tool in Elderly Patients with Multiple Myeloma

Ji Yun Lee - American Society of Hematology (ASH) , 2022

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Multiple Myeloma

Lenalidomide

Limited Long-Term Benefit of Upfront Autologous Stem Cell Transplant on Survival in Severe Renal Impairment in Multiple Myeloma in Novel Drug Era, a Retrospective Multi-Center Study in China

Huixing Zhou - American Society of Hematology (ASH) , 2022

Therapeutic Area

Disease

Drug/Treatment

Nephrology

Multiple Myeloma

N/A

Myc Translocation Is a Notable Marker on the Development and Relapse of Extramedullary Disease in Multiple Myeloma

Yuhang Song - American Society of Hematology (ASH) , 2022

Therapeutic Area

Disease

Drug/Treatment

Musculoskeletal

Multiple Myeloma

Thalidomide

Serum Ferritin Increased the Predictive Value of the International Staging System/Revised International Staging System for Overall Survival

Mengmeng Dong - American Society of Hematology (ASH) , 2022

Therapeutic Area

Disease

Drug/Treatment

N/A

Establishment of Patient-Derived Xenograft (PDX) Zebrafish Model of Multiple Myeloma and Its Application in Drug Screening

Zhen Yu - American Society of Hematology (ASH) , 2022

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Multiple Myeloma

DMSO

Evaluation of Daratumumab for the Treatment of Multiple Myeloma in Patients with Renal Insufficiency: A Systematic Review and Meta-Analysis

Weijun Fu - American Society of Hematology (ASH) , 2022

Therapeutic Area

Disease

Drug/Treatment

Nephrology

Renal insufficiency

daratumumab Intravenous

Filters

24782 Abstracts